Bishal Gyawali, Associate Professor at Queen’s University, shared an article by S.S. Datta on LinkedIn, adding:

“The best part of our paper is the quotes.

These quotes give you a clear picture of the ground reality.”

A clear picture of the ground reality

What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs.

Authors: S.S. Datta, et al.

A clear picture of the ground reality

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.